Wells Fargo & Company MN Acquires 965,842 Shares of Ignyta Inc (RXDX)

Wells Fargo & Company MN lifted its holdings in shares of Ignyta Inc (NASDAQ:RXDX) by 4,314.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 988,227 shares of the biopharmaceutical company’s stock after acquiring an additional 965,842 shares during the quarter. Wells Fargo & Company MN owned about 1.49% of Ignyta worth $12,206,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of RXDX. Vanguard Group Inc. lifted its holdings in shares of Ignyta by 10.4% during the 1st quarter. Vanguard Group Inc. now owns 1,228,177 shares of the biopharmaceutical company’s stock valued at $10,562,000 after acquiring an additional 115,212 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Ignyta by 4.5% in the 1st quarter. Geode Capital Management LLC now owns 241,615 shares of the biopharmaceutical company’s stock worth $2,077,000 after buying an additional 10,471 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Ignyta by 6.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 61,114 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 3,946 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Ignyta by 58.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 91,645 shares of the biopharmaceutical company’s stock worth $789,000 after buying an additional 33,900 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY acquired a new position in Ignyta in the 1st quarter worth $201,000. Institutional investors and hedge funds own 72.86% of the company’s stock.

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $20.00 price objective (up previously from $18.00) on shares of Ignyta in a report on Thursday, October 12th. Cantor Fitzgerald set a $23.00 price objective on shares of Ignyta and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research lowered shares of Ignyta from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Jefferies Group lowered shares of Ignyta from a “buy” rating to a “hold” rating and set a $27.00 price objective on the stock. in a report on Friday. Finally, Ladenburg Thalmann Financial Services boosted their price objective on shares of Ignyta from $20.25 to $31.00 in a report on Wednesday, October 18th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $23.80.

Shares of Ignyta Inc (RXDX) opened at $26.85 on Monday. The stock has a market cap of $3,080.00, a PE ratio of -9.91 and a beta of 206.06. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.07 and a quick ratio of 6.07. Ignyta Inc has a 12 month low of $4.60 and a 12 month high of $26.85.

Ignyta (NASDAQ:RXDX) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.03. sell-side analysts forecast that Ignyta Inc will post -2.27 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/25/wells-fargo-company-mn-acquires-965842-shares-of-ignyta-inc-rxdx.html.

Ignyta Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit